<SEC-DOCUMENT>0001683168-18-003156.txt : 20181026
<SEC-HEADER>0001683168-18-003156.hdr.sgml : 20181026
<ACCEPTANCE-DATETIME>20181026151625
ACCESSION NUMBER:		0001683168-18-003156
CONFORMED SUBMISSION TYPE:	1-A/A
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20181026
DATE AS OF CHANGE:		20181026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CNS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001729427
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				822318545
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		1-A/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	024-10855
		FILM NUMBER:		181141509

	BUSINESS ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
		BUSINESS PHONE:		1-800-946-9185 X701

	MAIL ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
</SEC-HEADER>
<DOCUMENT>
<TYPE>1-A/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xmlns="http://www.sec.gov/edgar/rega/oneafiler" xmlns:ns1="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>1-A/A</submissionType>
    <filerInfo>
      <liveTestFlag>LIVE</liveTestFlag>
      <filer>
        <issuerCredentials>
          <cik>0001729427</cik>
          <ccc>XXXXXXXX</ccc>
        </issuerCredentials>
        <offeringFileNumber>024-10855</offeringFileNumber>
      </filer>
      <flags>
        <sinceLastFiling>true</sinceLastFiling>
      </flags>
    </filerInfo>
  </headerData>
  <formData>
    <employeesInfo>
      <issuerName>CNS Pharmaceuticals, Inc.</issuerName>
      <jurisdictionOrganization>NV</jurisdictionOrganization>
      <yearIncorporation>2017</yearIncorporation>
      <cik>0001729427</cik>
      <sicCode>2834</sicCode>
      <irsNum>82-2318545</irsNum>
      <fullTimeEmployees>0</fullTimeEmployees>
      <partTimeEmployees>4</partTimeEmployees>
    </employeesInfo>
    <issuerInfo>
      <street1>2100 WEST LOOP SOUTH</street1>
      <street2>SUITE 900</street2>
      <city>HOUSTON</city>
      <stateOrCountry>TX</stateOrCountry>
      <zipCode>77027</zipCode>
      <phoneNumber>800-946-9185</phoneNumber>
      <connectionName>Matthew Lourie</connectionName>
      <industryGroup>Other</industryGroup>
      <cashEquivalents>380687.00</cashEquivalents>
      <investmentSecurities>0.00</investmentSecurities>
      <accountsReceivable>0.00</accountsReceivable>
      <propertyPlantEquipment>0.00</propertyPlantEquipment>
      <totalAssets>915032.00</totalAssets>
      <accountsPayable>84006.00</accountsPayable>
      <longTermDebt>1015165.00</longTermDebt>
      <totalLiabilities>1099171.00</totalLiabilities>
      <totalStockholderEquity>-184139.00</totalStockholderEquity>
      <totalLiabilitiesAndEquity>915032.00</totalLiabilitiesAndEquity>
      <totalRevenues>0.00</totalRevenues>
      <costAndExpensesApplToRevenues>0.00</costAndExpensesApplToRevenues>
      <depreciationAndAmortization>0.00</depreciationAndAmortization>
      <netIncome>-567182.00</netIncome>
      <earningsPerShareBasic>-0.05</earningsPerShareBasic>
      <earningsPerShareDiluted>-0.05</earningsPerShareDiluted>
      <nameAuditor>GBH CPAs, PC</nameAuditor>
    </issuerInfo>
    <commonEquity>
      <commonEquityClassName>Common Equity</commonEquityClassName>
      <outstandingCommonEquity>10536004</outstandingCommonEquity>
      <commonCusipEquity>000000N/A</commonCusipEquity>
      <publiclyTradedCommonEquity>N/A</publiclyTradedCommonEquity>
    </commonEquity>
    <preferredEquity>
      <preferredEquityClassName>None</preferredEquityClassName>
      <outstandingPreferredEquity>0</outstandingPreferredEquity>
      <preferredCusipEquity>000000N/A</preferredCusipEquity>
      <publiclyTradedPreferredEquity>N/A</publiclyTradedPreferredEquity>
    </preferredEquity>
    <debtSecurities>
      <debtSecuritiesClassName>Convertible notes payable</debtSecuritiesClassName>
      <outstandingDebtSecurities>386825</outstandingDebtSecurities>
      <cusipDebtSecurities>000000N/A</cusipDebtSecurities>
      <publiclyTradedDebtSecurities>N/A</publiclyTradedDebtSecurities>
    </debtSecurities>
    <issuerEligibility>
      <certifyIfTrue>true</certifyIfTrue>
    </issuerEligibility>
    <applicationRule262>
      <certifyIfNotDisqualified>true</certifyIfNotDisqualified>
    </applicationRule262>
    <summaryInfo>
      <indicateTier1Tier2Offering>Tier2</indicateTier1Tier2Offering>
      <financialStatementAuditStatus>Audited</financialStatementAuditStatus>
      <securitiesOfferedTypes>Equity (common or preferred stock)</securitiesOfferedTypes>
      <securitiesOfferedTypes>Security to be acquired upon exercise of option, warrant or other right to acquire security</securitiesOfferedTypes>
      <offerDelayedContinuousFlag>Y</offerDelayedContinuousFlag>
      <offeringYearFlag>N</offeringYearFlag>
      <offeringAfterQualifFlag>N</offeringAfterQualifFlag>
      <offeringBestEffortsFlag>Y</offeringBestEffortsFlag>
      <solicitationProposedOfferingFlag>N</solicitationProposedOfferingFlag>
      <resaleSecuritiesAffiliatesFlag>N</resaleSecuritiesAffiliatesFlag>
      <securitiesOffered>2875000</securitiesOffered>
      <outstandingSecurities>10536004</outstandingSecurities>
      <pricePerSecurity>6.0000</pricePerSecurity>
      <issuerAggregateOffering>17250000.00</issuerAggregateOffering>
      <securityHolderAggegate>0.00</securityHolderAggegate>
      <qualificationOfferingAggregate>0.00</qualificationOfferingAggregate>
      <concurrentOfferingAggregate>0.00</concurrentOfferingAggregate>
      <totalAggregateOffering>17250000.00</totalAggregateOffering>
      <underwritersServiceProviderName>Boustead Securities, LLC</underwritersServiceProviderName>
      <underwritersFees>1207500.00</underwritersFees>
      <auditorServiceProviderName>GBH CPAs, PC</auditorServiceProviderName>
      <auditorFees>17000.00</auditorFees>
      <legalServiceProviderName>Schiff Hardin LLP</legalServiceProviderName>
      <legalFees>170000.00</legalFees>
      <estimatedNetAmount>15667500.00</estimatedNetAmount>
    </summaryInfo>
    <juridictionSecuritiesOffered>
      <jurisdictionsOfSecOfferedSame>true</jurisdictionsOfSecOfferedSame>
      <issueJuridicationSecuritiesOffering>AL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AK</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AZ</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CO</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>DE</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>FL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>GA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>HI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ID</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>KS</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>KY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>LA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ME</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MD</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MS</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MO</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NE</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NV</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NH</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NJ</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NM</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ND</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OH</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OK</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>PA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>RI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>SC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>SD</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>TN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>TX</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>UT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>VT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>VA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WV</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>DC</issueJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AK</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AZ</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CO</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>DE</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>FL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>GA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>HI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ID</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>KS</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>KY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>LA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ME</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MD</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MS</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MO</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NE</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NV</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NH</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NJ</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NM</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ND</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OH</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OK</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>PA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>RI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>SC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>SD</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>TN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>TX</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>UT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>VT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>VA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WV</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>DC</dealersJuridicationSecuritiesOffering>
    </juridictionSecuritiesOffered>
    <securitiesIssued>
      <securitiesIssuerName>CNS Pharmaceuticals, Inc.</securitiesIssuerName>
      <securitiesIssuerTitle>Common Stock</securitiesIssuerTitle>
      <securitiesIssuedTotalAmount>327004</securitiesIssuedTotalAmount>
      <securitiesPrincipalHolderAmount>0</securitiesPrincipalHolderAmount>
      <securitiesIssuedAggregateAmount>$490,500; common stock sold for $1.50 per share</securitiesIssuedAggregateAmount>
    </securitiesIssued>
    <securitiesIssued>
      <securitiesIssuerName>CNS Pharmaceuticals, Inc.</securitiesIssuerName>
      <securitiesIssuerTitle>Convertible notes</securitiesIssuerTitle>
      <securitiesIssuedTotalAmount>386825</securitiesIssuedTotalAmount>
      <securitiesPrincipalHolderAmount>0</securitiesPrincipalHolderAmount>
      <securitiesIssuedAggregateAmount>386825</securitiesIssuedAggregateAmount>
    </securitiesIssued>
    <unregisteredSecuritiesAct>
      <securitiesActExcemption>Section 4 (a)(2) of the Securities Act of 1933</securitiesActExcemption>
    </unregisteredSecuritiesAct>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>PART II AND III
<SEQUENCE>2
<FILENAME>cns_1aa3.htm
<DESCRIPTION>POC AMEND NO. 3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Amendment No. 3 to the Offering Statement on Form 1-A filed
by CNS Pharmaceuticals, Inc. is being filed solely to include Exhibits 9.1 and 12.1. Accordingly, this Amendment No. 3 consists only
of Part I, this explanatory note, the signature page, the exhibit index, and the exhibits. The Preliminary Offering Circular is
unchanged and has therefore been omitted.</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART III &ndash; EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 7%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="width: 93%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1 </FONT></TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818002664/cns_a1-ex0101.htm" STYLE="-sec-extract: exhibit">Form
    of Underwriting Agreement (3)</A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818003041/cns_1aa2-ex0102.htm" STYLE="-sec-extract: exhibit">Form of Issuer Acknowledgment
    Regulation A Offering between CNS Pharmaceuticals, Inc., FinTech Clearing, LLC and FinTech Global Markets, Inc. (4)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001028/filename3.htm">Amended and Restated Articles
    of Incorporation of CNS Pharmaceuticals, Inc. (1)</A> </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001028/filename4.htm">Amended and Restated Bylaws
    of CNS Pharmaceuticals, Inc. (1)</A> </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0301.htm" STYLE="-sec-extract: exhibit">Form
of convertible promissory note issued to debt holders (2)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0302.htm">Form of warrant issued to convertible
    debt holders (2)</A> </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0303.htm">Form of SAFE agreement used
    in Regulation CF offering (2)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.4 </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818002664/cns_a1-ex0304.htm" STYLE="-sec-extract: exhibit">Form
    of Underwriter Warrant (3)</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818002664/cns_a1-ex04.htm" STYLE="-sec-extract: exhibit">Subscription
    Agreement for Offering (3)</A>     </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0601.htm" STYLE="-sec-extract: exhibit">Amended
And Restated Patent License Agreement effective as of December 28, 2017 between CNS Pharmaceuticals, Inc. and Houston Pharmaceuticals,
Inc. (2)</A></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0602.htm">Collaboration and Asset Purchase
    Agreement between CNS Pharmaceuticals, Inc. and Reata Pharmaceuticals, Inc. dated November 21, 2017 (2)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0603.htm" STYLE="-sec-extract: exhibit">2017 Stock Plan of CNS
    Pharmaceuticals, Inc. (2)</A></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0604.htm" STYLE="-sec-extract: exhibit">Employment Agreement between CNS
    Pharmaceuticals, Inc. and John M. Climaco dated September 1, 2017 (2)</A></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818001713/cns_a1-ex0605.htm">Consulting Agreement between
    CNS Pharmaceuticals, Inc. and Fresh Notion Financial Services dated July 27, 2017 (2)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.6 </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818002664/cns_a1-ex0606.htm" STYLE="-sec-extract: exhibit">Sublicense Agreement between CNS
    Pharmaceuticals, Inc. and WPD Pharmaceuticals, Inc. dated August 30, 2018 (3)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.7 </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818002664/cns_a1-ex0607.htm" STYLE="-sec-extract: exhibit">Sublicense Agreement between CNS
    Pharmaceuticals, Inc. and Animal Life Sciences, LLC. dated August 31, 2018 (3)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.1 </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818003041/cns_1aa2-ex0801.htm" STYLE="-sec-extract: exhibit">Form of Offering Deposit Account
    Agency Agreement with FinTech Clearing, LLC (4)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>9.1</TD>
    <TD><A HREF="cns_1aa3-ex0901.htm">Letter Regarding Change in Certifying Accountant</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10 </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Power of Attorney (previously filed)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Consent of GBH CPAs, PC</FONT>
    (previously filed)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of The Loev Law Firm, PC (included in
Exhibit 12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</FONT></TD>
    <TD><A HREF="cns_1aa3-ex1201.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of The Loev Law Firm, PC as to legality of the securities being registered</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1729427/000168316818003041/cns_1aa2-ex1501.htm" STYLE="-sec-extract: exhibit">Terms of Use &ndash; FlashFunders.com (4)</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">_________________________</P>



















































































































































































































































<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px">(1)</TD>
    <TD>Included with Form DOS filed April 17, 2018 and incorporated by reference</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD>Included with Form 1-A filed on June 15, 2018 and incorporated by reference</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(3)</TD>
    <TD>Included with Form 1-A/A filed September 10, 2018 and incorporated by reference<BR>
</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(4)</TD>
    <TD>Included with Form 1-A/A filed October 12, 2018 and incorporated by reference</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of Regulation
A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A
and has duly caused this amendment to Offering Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in the City of Houston, State of Texas on October 26, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNS Pharmaceuticals, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-indent: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ John M. Climaco</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John M. Climaco</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This offering statement has been signed
below by the following persons in the capacities and on the dates indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>SIGNATURE</B></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>TITLE</B></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 20%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>DATE</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John M. Climaco</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John M. Climaco</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, President and Chief Executive Officer (principal executive officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 26, 2018 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/&nbsp;s/ Matthew Lourie</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Lourie</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer (principal financial and accounting officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 26, 2018 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerzy (George) Gumulka</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 26, 2018 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffry Keyes </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 26, 2018 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carl Evans </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 26, 2018 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrzej Andraczke </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 26, 2018 </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;By: <U>/s/ Matthew Lourie&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Matthew Lourie</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attorney-in fact</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-9 ACCT LTR
<SEQUENCE>3
<FILENAME>cns_1aa3-ex0901.htm
<DESCRIPTION>ACCOUNTING LETTER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0">Exhibit 9.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of the Chief Accountant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C.&nbsp;&nbsp;20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentleman:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have read the statements under the heading &ldquo;Experts&rdquo;
in the Offering Statement on Form 1-A (Amendment No. 2) dated October 12, 2018, of CNS Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
filed with the Securities and Exchange Commission and we agree with such statements therein as related to our firm. We have no
basis to agree or disagree with the other statements that relate to Marcum LLP made by the Company in the Form 1-A (Amendment No.
2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="color: #0D0D0D; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="color: #0D0D0D; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ GBH CPAs, PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GBH CPAs, PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.gbhcpas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 26, 2018</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-12 OPN CNSL
<SEQUENCE>4
<FILENAME>cns_1aa3-ex1201.htm
<DESCRIPTION>OPINION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0">Exhibit 12.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">October 26, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2100 West Loop South, Suite 900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Houston, TX 77027</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Re:&#9;<U>CNS Pharmaceuticals, Inc.,
Offering Statement on Form 1-A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">We have acted as special
counsel to CNS Pharmaceuticals, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the filing of
the above referenced Offering Statement (as amended from time to time, the &ldquo;<U>Offering Statement</U>&rdquo;) under Regulation
A of the Securities Act of 1933, as amended (the &ldquo;<U>Act</U>&rdquo;), with the Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;).
The Offering Statement relates to the proposed offering and sale of (i) up to 2,875,000 shares of common stock, par value $0.001
per share, of the Company (the &ldquo;<U>Shares</U>&rdquo;); and (ii) the issuance of a warrant to the underwriters of the Shares
(the &ldquo;<U>Warrants</U>&rdquo;) to purchase that number of shares of common stock as contemplated pursuant to the Offering
Statement (the &ldquo;<U>Warrant Shares</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">In connection with
this opinion, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of rendering
the opinions expressed below. In addition, we have been furnished with and have examined originals or copies of the Offering Statement
and related offering circular, the corporate proceedings taken by the Company with respect to the filing of the Offering Statement
and related offering circular and the issuance of the Shares and Warrants, and the originals or copies certified to our satisfaction
of such records, documents, certificates, memoranda and other instruments as we have considered necessary to provide a basis for
the opinions hereinafter expressed, including, without limitation (a) the Articles of Incorporation of the Company, as amended
to date, (b) the Bylaws of the Company, as amended to date, (c) certain resolutions adopted by the Board of Directors of the Company
or authorized committees thereof (either at meetings or by unanimous written consent), (d) the form of Common Stock Purchase Warrant
evidencing and documenting the Warrants (the &ldquo;<U>Warrant Agreement</U>&rdquo;); (e) the form of Subscription Agreement relating
to the subscription for the Shares (the &ldquo;<U>Subscription</U>&rdquo;); (f) the form of Underwriting Agreement in connection
with the offering described in the Offering Statement (the &ldquo;<U>Underwriting Agreement</U>&rdquo;); and (g) such other documents
and records and matters of law as we have deemed necessary or appropriate for purposes of this opinion. In such examination, we
have assumed that the documents and instruments submitted to us have not been amended or modified since the date submitted and
the due execution and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">As to facts material
to the opinions expressed herein, we have relied upon oral or written statements and representations of officers and other representatives
of the Company and others and have not independently checked or verified the accuracy of such statements and representations. The
opinions contained in this letter are expressed as of the date hereof, and we do not have, nor do we assume, any obligation to
advise of any changes in any facts or applicable laws after the date hereof that may affect the opinions we express herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">Also, we have relied
as to certain matters on information obtained from public officials, officers of the Company and other sources believed by us to
be responsible, and we have assumed, without independent verification, that all governing documents under which the Shares and
Warrants are to be issued will have been duly authorized, executed and delivered by all parties thereto, and the signatures on
documents examined by us are genuine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">In rendering this
opinion, we have assumed: (i) information contained in documents reviewed by us is true, complete and correct; (ii) the genuineness
and authenticity of all signatures; (iii) the authenticity of all documents submitted to us as originals; (iv) the conformity to
authentic originals of all documents submitted to us as copies; (v) the accuracy, completeness and authenticity of certificates
of public officials; (vi) the due authorization, execution and delivery of all documents by parties other than the Company; (vii)&nbsp;the
obligations of parties other than the Company to the Warrant Agreement, Underwriting Agreement and Subscription being valid, binding
and enforceable; (viii) the legal capacity of all natural persons; (ix) the Offering Statement, and any amendments thereto, has
or will have become qualified (and will remain qualified at the time of issuance of any Shares, Warrants and Warrant Shares (as
defined below) thereunder); (x) the Company will issue and deliver the Shares in the manner contemplated by the Offering Statement
and Subscription and the shares of common stock issuable upon exercise of the Warrant (the &ldquo;<U>Warrant Shares</U>&rdquo;),
as contemplated by the Underwriting Agreement and Warrant, and will receive the full amount of the consideration for which the
Board of Directors (or any duly authorized pricing committee or designee thereof) authorized the issuance of the Shares and Warrant
Shares; (xi) the resolutions authorizing the Company to issue, offer and sell the Shares and Warrants will be in full force and
effect at all times at which the Shares and Warrants are offered, issued and sold by the Company; and (xii) the Company will issue
a share certificate or certificates to each purchaser of the Shares and Warrant Shares certifying the number of Shares and Warrant
Shares held by such purchaser, or such Shares and Warrant Shares will be registered by book entry registration in the name of such
purchaser, if uncertificated. We express no opinion as to the enforceability of the Underwriting Agreement, Subscription or Warrant
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">We have also assumed
that (i) shares of common stock of the Company will remain authorized and available for issuance of the Warrant Shares upon exercise
of the Warrants; and (ii) none of the Company&rsquo;s charter documents, or the corporate proceedings taken by the Company with
respect to the filing of the Offering Statement and the issuance of the Shares and grant of the Warrants, will be rescinded, amended
or otherwise modified prior to the issuance of the Shares and grant of the Warrants and no Shares or Warrant Shares will be issued
or other action taken in contravention of any applicable limit established pursuant to such resolutions from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">Based upon the foregoing,
we are of the opinion that (i) the Shares have been duly authorized by the Company and, when issued and sold by the Company and
delivered by the Company against receipt of the purchase price therefor, in the manner contemplated by the Offering Statement and
Subscription (and subject to the minimum offering amounts described in the Offering Statement), will be validly issued, fully paid
and non-assessable; (ii) the Warrants being acquired pursuant to the Offering Statement, Underwriting Agreement and Warrant Agreement,
when issued and acquired as contemplated in the Offering Statement, Underwriting Agreement and Warrant Agreement will be duly authorized
and constitute valid and legally binding obligations of the Company; and (iii) the Warrant Shares, when issued and paid for in
accordance with the terms of the Warrant Agreement and as contemplated by the Offering Statement, will be duly authorized, validly
issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">The foregoing opinions
are limited to the State of Nevada. We express no opinion herein as to any other laws, statutes, ordinances, rules, or regulations
(and in particular, we express no opinion as to any effect that such other laws, statutes, ordinances, rules, or regulations may
have on the opinions expressed herein). No opinion is expressed herein with respect to the qualification of the Shares, Warrants
or Warrant Shares under the securities or blue sky laws of any state or any foreign jurisdiction. This opinion is limited to the
matters set forth herein, and no other opinion should be inferred beyond the matters expressly stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">Our opinion is as
of the date hereof and we have no responsibility to update this opinion for events and circumstances occurring after the date hereof
or as to facts relating to prior events that are subsequently brought to our attention and we disavow any undertaking to advise
you of any changes in law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">We hereby consent
to the use of this opinion as Exhibit 12 to the Offering Statement and to the reference to us under the caption &ldquo;<U>Legal
Matters</U>&rdquo; in the Offering Circular included in the Offering Statement. In giving such consent, we do not hereby admit
that we are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations
of the SEC thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><I>/s/ The Loev Law Firm, PC</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #= SL# 2(  A$! Q$!_\0
M'  ! 0 " P$!              8%!P(#! $(_\0 1!   0,# @(&"0(% @4$
M P$! 0(#!  %$082(3$'$Q1!4585%R)489*5HM%QTR,R4H&1"$(6,V*AL4-R
M@L$D)5,TLO_$ !@! 0$! 0$                ! @,$_\0 *1$! 0 ! @0&
M 04!          $" Q$$$B&1!3%!46'1%"-QDJ&Q@?_:  P# 0 "$0,1 #\
M_5-*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%8'4VL+!IAQAN_7-B$MX%38<S[0'/D*SU<'&6G<=:VA>.6Y(-!$^MG
M0OF2%]WXIZV="^9(7W?BK/LD;W=GY!3LD;W=GY!01GK9T+YDA?=^*>MG0OF2
M%]WXJS[)&]W9^04[)&]W9^04$9ZV="^9(7W?BGK9T+YDA?=^*L^R1O=V?D%.
MR1O=V?D%!&>MG0OF2%]WXIZV="^9(7W?BK/LD;W=GY!3LD;W=GY!01GK9T+Y
MDA?=^*>MG0OF2%]WXJS[)&]W9^04[)&]W9^04$9ZV="^9(7W?BGK9T+YDA?=
M^*L^R1O=V?D%.R1O=V?D%!&>MG0OF2%]WXIZV="^9(7W?BK/LD;W=GY!3LD;
MW=GY!01GK9T+YDA?=^*>MG0OF2%]WXJS[)&]W9^04[)&]W9^04$9ZV="^9(7
MW?BGK9T+YDA?=^*L^R1O=V?D%.R1O=V?D%!&>MG0OF2%]WXIZV="^9(7W?BK
M/LD;W=GY!3LD;W=GY!01GK9T+YDA?=^*>MG0OF2%]WXJS[)&]W9^04[)&]W9
M^04$9ZV="^9(7W?BGK9T+YDA?=^*L^R1O=V?D%.R1O=V?D%!&>MG0OF2%]WX
MIZV="^9(7W?BK/LD;W=GY!3LD;W=GY!01GK9T+YDA?=^*>MG0OF2%]WXJS[)
M&]W9^04[)&]W9^04$9ZV="^9(7W?BGK9T+YDA?=^*L^R1O=V?D%.R1O=V?D%
M!&>MG0OF2%]WXIZV="^9(7W?BK/LD;W=GY!3LD;W=GY!01GK9T+YDA?=^*>M
MG0OF2%]WXJS[)&]W9^04[)&]W9^04$9ZV="^9(7W?BGK9T+YDA?=^*L^R1O=
MV?D%.R1O=V?D%!&>MG0OF2%]WXIZV="^9(7W?BK/LD;W=GY!3LD;W=GY!01G
MK9T+YDA?=^*>MG0OF2%]WXJS[)&]W9^04[)&]W9^04$9ZV="^9(7W?BGK9T+
MYDA?=^*L^R1O=V?D%.R1O=V?D%!&>MG0OF2%]WXIZV="^9(7W?BK/LD;W=GY
M!3LD;W=GY!01GK9T+YDA?=^*>MG0OF2%]WXJS[)&]W9^04[)&]W9^04$9ZV=
M"^9(7W?BGK9T+YDA?=^*L^R1O=V?D%.R1O=V?D%!&>MG0OF2%]WXIZV="^9(
M7W?BK/LD;W=GY!3LD;W=GY!01GK9T+YDA?=^*>MG0OF2%]WXJS[)&]W9^04[
M)&]W9^04$9ZV="^9(7W?BGK9T+YDA?=^*L^R1O=V?D%.R1O=V?D%!&>MG0OF
M2%]WXIZV="^9(7W?BK/LD;W=GY!3LD;W=GY!01GK9T+YDA?=^*>MG0OF2%]W
MXJS[)&]W9^04[)&]W9^04$9ZV="^9(7W?BGK9T+YDA?=^*L^R1O=V?D%.R1O
M=V?D%!&>MG0OF2%]WXIZV="^9(7W?BK/LD;W=GY!3LD;W=GY!01GK9T+YDA?
M=^*>MG0OF2%]WXJS[)&]W9^04[)&]W9^04$9ZV="^9(7W?BGK9T+YDA?=^*L
M^R1O=V?D%.R1O=V?D%!&>MG0OF2%]WXIZV="^9(7W?BK/LD;W=GY!3LD;W=G
MY!01GK9T+YDA?=^*>MG0OF2%]WXJS[)&]W9^04[)&]W9^04$9ZV="^9(7W?B
MGK9T+YDA?=^*L^R1O=V?D%.R1O=V?D%!&>MG0OF2%]WXIZV="^9(7W?BK/LD
M;W=GY!3LD;W=GY!01GK9T+YDA?=^*>MG0OF2%]WXJS[)&]W9^04[)&]W9^04
M$9ZV="^9(7W?BGK9T+YDA?=^*L^R1O=V?D%.R1O=V?D%!&>MG0OF2%]WXIZV
M="^9(7W?BK/LD;W=GY!3LD;W=GY!01GK9T+YDA?=^*>MG0OF2%]WXJS[)&]W
M9^04[)&]W9^04$9ZV="^9(7W?BGK9T+YDA?=^*L^R1O=V?D%.R1O=V?D%!&>
MMG0OF2%]WXIZV="^9(7W?BK/LD;W=GY!3LD;W=GY!01GK9T+YDA?=^*>MG0O
MF2%]WXJS[)&]W9^04[)&]W9^04$9ZV="^9(7W?BGK9T+YDA?=^*L^R1O=V?D
M%.R1O=V?D%!&>MG0OF2%]WXK-::UC8-3NO-V&YL35L@*<#>?9!Y9R*S/9(WN
M[/R"N;;+31):;0C//:D"@YTI2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4) YU#:\UC,MEPCV'3,1J;J"2V7?XR
MB&HK><=8YCCQ/)(XG%2,_0^N9D)ZX7OI'EPPVA3RVX,1#;: !DXR22,4&Y\C
MQK"WC5-FL]VA6RX3V6+A-2I4=A1]IP)YD5^9^A:3K[6[+TI.M9T9A+ZFFNLC
MH=W) '$\O&LMT]:?EZ;L46\W>^2;OJ)]0MT!Q3:6DL!?\ZD)3WXX9)/.@V)K
M7IYT?IB0J,')=RD).U8AL[D(/@5G"<_ $U>Z3O[6H[4Q/CM.M,O(#B ZG:K!
M&>(J;Z*[!$@:9BQU1VBAEI+8"D@\0.)_4G)J];0AM.&TI2/!(H.5*$@<SB@.
M>5 I2M>],/2(C0MLB,PF$3+]<G.I@Q2>:N WJQQVC(_6@V$2!SI6CY^C=?WB
MRLW:VZTF-7P$+5'6 F*YXI"0. \"<UMS3C,]BVM(NKB')02-Y1RW8XX^&:#*
M4I0$'D0:!2E 0>1% I3-,CQ% I0$$9%*!3(\:U-TG](TR'JB'HS275*OLE/6
M29*AO3":\=O>HCD#XCQKQ.:'UW&O=KNEHU?+F15K';HEQ4""CO4C:  ?APH-
MS4KH@I=1%;3(.7 .)KOH%*^;AG&17V@4ID>-,@\J!2F1G&>-*!2M;7#5E\U+
M=9%NT/V:/"CK++UWD(+H4L<TLHR K!X%1.,\.-:C7J;6\OIBF:0BZKD.1HB0
M7Y"8S8(7@$@#&.:@*#]2YKXM24(*EJ"4@9))P!6G=6:7UK L[,BW:TNDF0J0
MRV61%;.4J6 KBE.1@$G/PJSU'I=>K-"SK#<9\F)VM(2J0R<+ "@?\'&"/ T%
M:T\V\G+2TK'/*3FN=3FAM+L:3LD:VQI#K[+#:6TK=.5$#O-4#CK;2"MQQ"$C
MF5' H.=*XH<0L92H$>(-<LCQ% I3(QG(I0*4KA(>:CL.//N(;:;25+6LX"0.
M9)H.="0.9K54_6&HM3-R'=),^CK&TE2O23S!>?D =[+/#@>Y2N?<*CM$W%&O
MY$MNV:TU8'(ZPV7U!II)5\$;<</CXT'Z&!SRI7YNM.O]3:,Z57=$ZHFINC2@
M%QINP(6M*AN&X#AXC]15SKKI3=CW:/IG1T=J?J-] 6ZM:LLPDG_<YCF?!/Z4
M&V"0.=,YK5MOT'J"Y1.TWG6M\3/6,A4926FT'X-XQCX'->#HAN^K'KK>K;J2
M6W+3;IRX:'TM["X$@'<<<.1%!N&E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4&A8<ZXV[_4'J>+,@2'&YS<=Z-(""4!I"<;<_JH_P!Q
M5GT^WXV+H@OTI)V.OL=F1XY<]G_P36QR >8!K\[?ZL9_I.1I#1\=SVY\X/OI
M',('LC__ *4?[4%)_ILL7HK15O"D866>L5_[E^T?_-1O^IJ[(D=)VA[,L+=9
MB[ISC38W*6HJ&U('C[!'_P JWGH:*B':^H;2 E& #_:M#P4(U7_J*U9<UD*C
MV=*(;9/(*' C[5T&$Z8;OKBUP=-=GOB[:JXR>K8MT'*=N,<5N<UG)'#&*W?<
M=9IT7T<2+[>UE]QL!#38X%YT\$I'ZG_MFM1:L6-6_P"H.+"44H@:<@I<7D^R
MA9 ))/ZK3_BL?T]WA&H-2:"T];924PG%A_K1A2"HKVI5X'&#_F@]'2I<-5M:
M>LUW.J+DWJ:?)0EFVQ'-C(!XE*4 <0G(!4<YK]$Z"7<%V%A5U5ND;1O/QQQ_
M[UKBT6_2FC9<>=?9#LZ^R5!AEQ[+LAPDXVH2![*1GN  [ZW#;9+<F,%,H*$@
M[<&@]5?EF9(5KC_4S/<4HNP[$CLS([DJ' _<5?XK]*ZBNK%CL4^YRUI2S$86
M\HD^ S7YU_TR6IY4>;J6<@J?N\Y3@)[TY/'_ "54'Z6B-!B,VVD8"4@5U7:X
M1K3;)4^>X&HL9M3KJS_M2!DUUW2ZQK;;)LUY16W$94\XEOVE;4I).!XX%?G[
MIXZ1&M2=!+DZR-NHB7)YIHJ7P4$;B2"/U1B@S=@D:@Z7&I-Q5>;A8K(Z5"!&
M@+#:R@' <=5C))_I!Q4QT%ZUU!&UG>])ZAN#MP7;7E-I>=.5$!92<GF>[&?&
MMB="DR%;.CZU/+>;3&$!#A</ )"4 G_[K3&EV'XULZ0>D8A3)G*?<@ CB4E2
ML+_R1_B@VC=-82M=ZFN]KM%W?M&F[3EJ3-C+"'7W0"5860=J$_#B?TK671SK
M36-LLTU]$V;<H<BZH@P)DI"GBA"E$%TCF1C&!GG7/H'TA NFA6IVH+@ZNUNO
M..NQ"O8R2#@J<(XJY X)Q\*_0^A;Y8+E#2WIQLF"A19;<2V4(5M_IR!E/Q'"
M@T5K74&HG=>VS2-LU7>7;D[AR>\DMM(9;(SM2E"!A6._/#(K8/3)#ND'HSMA
M@7:6S<&KC$"5!P[GLK"=JCW\\_VK6&GFNR_ZI=8&<0%IZQU!6<#9E"AQ_P#:
M1_BMHKN#G2!J2#,9;4-.6IT]E/ODK!3O'BA ) />>/=0;,TR7C;$=>HJ7XFL
MC,D-Q(C\AY02TRA3BB>X 9-(C74QVT8Q@<16O?\ 4+J!.GNB>^.AP)?E-=C:
M'>5.>R<?VS0:@_T](=U;K?46K9H4M<V6I+:E<P@<<?XVC^U?J8#  '(5IG_3
MO81IW2-M8?2$O.,]<YDXP5>U_P#8K86NM8V[1NFWKU<0Z[%:6A!#"=RLJ.!W
M\J#+7RZP[':95RN;R6(<9LN.+5W ?_=:<U-=-::ETY/O\&^#2UE8CKD-L-QT
MN/J0!D%Q2OY2?Z4\L\ZP?3IJP:@O^B-,():M]PE(ER<_^J@$;$GX9SP_2N?^
MH/6$6R=%DBP17!Z4N2TM%M(XI:SE2CX9Q@?K08#HPU/JJ%T<W75DEZ9>+G(=
M2&@X"YM1N" K:.X94<#G7;TH:HU) N5HL4'5-V>U#<U))"$-,-1VR<9*4HSX
M\">&*V?T2+M^FK% LZW4F4U$;4ML$;D\ "2.X$YK4VL&,?ZL4F4H=6]&0MC/
M(#JN7^0J@J^ER^73H[Z%([<"Y3%7*8ZB(W*=<*G4@@J4K=SS@8^&:ONA5^[S
M-#05WR2Z[+5'3O=6?:R4\R?&M(?ZH=4,WJVV.) C*=A6R:$R)8(ZOK2G_E ]
MY !)[ARK:\O52X%E9TYI\)?OTYO#2D\4QVR/:>7X #D.\X H/+T"JNH:N34^
MX/SV6KE*:9><65;T)<QG)[L@U>]*EQDVGHYU%.@E0DLPG%-J3S2<8S_:G1]8
MV;)8XT6.D]4RV&TK5S6?]RC\2<G^]4LN,S,BO1I3:76'D%#B%#(4DC!!H-9]
M#,^VL]'D&5%4GL[$%#BB/@C*\_'.ZM%="5TN4G5NHM3L6"==G;A,4O?'4V-H
MW%1'M*'B/\5M_IH;L_1MT+7>+86$0NTH['';22>+A]HCO_E*C7W_ $W6 V'1
M=K0ZC#\ACM#F?]I7Q_\ ! H,WH[6]]O\6]R56)QIV+(<8C05J2EQ10E((4K.
M,E1/]JT[JF\:Y5TVV6SW#4;F[8)4F%!RB.PGB>K\5\ .*O&OU0U'98W%EIMO
M)*CM2!DGB3^M?E3H\GQ[]TM:TUA<7T-PF90BLN+.$[=V ,_HE/\ F@K>GW4F
MKK#H54F'<#9V"^W&9+1"GI.1E2BK_8GG@#CPXXY5/,:8U5TD:7CJG7&>JT1&
M4EF$TYM>G. 8WK6KD">7/AQK(=/]P9U;K?0FE6-W4!Y4R2A0QE(P!_V"_P#-
M;XTC';C6D(:2 E)QG&,T'Y<O5]U;8.ERWV#TQ+E]DC)6;?%44M=84'"">:DC
M()4KCP/Z4U9JO7%MZ6[5;W[W)FNEE+JK?$'5LI*@<(^(Y$J5Q_\ %9OHJ0G5
M'2CK;5C@WM":8S!QP*0?P$_YKIZ/$(U/TQ:TU.]QC,2.R1SW;4G'#^R!\U!X
M-0WS73'2YIVV2]2/../-)D/0XP+;#*#N]G'^[@.9XU^J[&73;&"^<N%.2:_+
M>@I+&I.EC5^L+@ZAF)%<$-DK.$A(PD?WPD#_ .5?H>'KBP+N1L[4YI5T9;"G
M(H/MI'CB@JZUWTPR#*38-.[BAB[S").#C<PT@N*1_P#(A(_3-;":<2ZVE:#E
M*AD&H#IFTA<]3V2#)TT^VQ?[5($J(IPX0O@0I"O@0?\ M0=NN;DUI7HIOES:
M"4*9A+V8X>T1M2!_<BM&?Z>M4::TCI(2+G/0N>\I;QC,@N/+43P2$CB3@#_-
M9+_4!>+NGHXL>F+FAMJZ7:2TEYMLD@;3D@>(W;:W)T962/:;.U#$=(+++:-^
MT<<#&/\ M0?GF\Q;S)ONH.EC5,%=OCL-[;="?X+!P$-[AW<^7B35=_I@TZM^
M"Y?;D2]/N+AD.NKXJ(SP'_D_WK/?ZP@XCHB2&$X;-P9#F/Z<+Q_WQ6>Z!@S'
MT?9TMD$/0VRD@?\ 3Q'_ )H-J@8&!RK$VFP0[7(EO1NL*Y4E<IPK.?;5C./A
MP%98D $DX KBVXAP$MJ2H#P.:#E2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2
ME*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2
ME*!2E*!2E*!2E*!2E*#SW&,9D%^,F0_&+J"CKF%!*T9[TDYP:U3)Z#K5(O2;
MN_=;T_=&_P#E3'IQ6XGYDD=YK;U*"/TQH^1904NWJ?-!6%E4AXJ4.'(8  %>
M;2W1K9],R;@[:UR-T^1VF0IY>]:U\<Y4>[B?\U<TH-83^ARQR-97+427)!>N
M..TQENGJ%\N:1_,. .#D9KCK[H7L.L6(*I+CT6="X-/QB$83_3@#D.[PK:-*
M#7^E.B^T6!U#X"I4L#!ER5EY]0\-ZN('P&!5ZTTAE 0TD)2.X5SI006O^C>/
MK20LW*[W<0G$A"X#4LML$#OV@<3GCQS4\.A.+'C-1[7J74]N8: 2AJ/=7 A(
M'<$@ "MO4H-/1^B"Y,A2'=9W^5'=]EUIV2"2GD?;*2H</"JIKHVL#FEUZ?FP
M67+4IL-ICI&$H X@@\]V>.>>:MZ4&G[)T)Q+0UV--YN<RT#^2!)E*ZG![B@<
M%#X'@?"K\Z1M3NGY%GDQFW(<ADL+;"=H"",82.[^U4-*#2^G.@"PV1;C8ES)
ML$K*TQ)3RE,Y\5-C"5']<UMBT6B):HZ&HK2$!"0E.U( 2!W =PK(4H-8ZDZ(
M[3>M?/ZHD%3C[["65L%12V<#!*@/Y\C P>'"KVT6>):V&VX[2!U8VIPD )'@
MD=PK(TH%:OU;T/6W55P,F]W6]3D!TO(8=G*#;2O^A(& !RY5M"E!J&7T,J6H
MJAZPU5&X<$^E7%C_ ,5\C]$,I2!%O.I;I>;=N"S&EO H44G("\)RH9QP)QPK
M;]*#6&NNARQZP9@.37)$>?"/\)^,O80G^GOX9Y8Y5C;UT%62\VN/#EOOM=4Z
M'5.-.%3CY P.L<5E2CQ./#-;AI02>E=$6ZPM%+3+>2<J.2I3A\5K/M+/ZU/Z
M]Z*(&J]:V[4CK[S;T1GJ2TRLM=8,G!*D\<8.,#NK9E*#6NLNB:TZDT4G3X*8
M32'D/(5'0$A!2>( Y<02,_&LSI'0ENT^T.K:272 ''5**W7L<BXL\5?H> JQ
MI0?$I2A(2D!*1P '=7VE*#6&M.AZUZON*I-\N5XFM%PN(CN35!MHGN0D# ']
MLUF=,:#1IXK$2YW)UM6T!$F6MX( _IS@"K:E!\4D*04G.",5JK270G8M,27E
MPW7Y"''^O"92RL-J[BE/+</ZL9K:U*"%?Z,[,O6*-3(4^+HEGJ 5KW(2G&/9
M3W&K!N$A%N5$2M:4J04E:3A7'F0>XUZJ4$+I'HTL^E+>[;[07FX;CBG5A2MR
MU*4 ,E7]A32'1I9])L/1K471$=>+[B73O4M1\55=4H-4V/H@L6E)$V7#?<,1
MQTRE)F.E3;"AQW)2?9R/ZCQ^-0VD]/Q+_P!+URUG:8[B;:4"/$6H8[4YC:MT
M#^G' 'OYU^BY+#4J.XQ);2ZRZDH6A8R% \P17G@VR'!QV1A#8 "0 .  Y >
MH.Z&T6(K;:CDI&":YOH+C+B$N*;4I) 6GFGXBN=*#4-XZ$;==KNU=+A>KU,N
M#!RQ(D2]ZFCG(P"DI SW "J73^A)%H=6XO4-UG*6G9B2[E*!G.4I  S\:N:4
M&!UII>#J[2LVQ75)7'DM[=W-2%#BE8^(.#6@M)LZ\Z*=]DN5BE7^U,KS"F0%
MC<A/AA1'#GP/+XU^FZ$ C! (^-!IH2-7:XEL(N;#EELC2DK5!0[F3+P>3JD\
M$(\0#QY&ML6F&8<;:K&]7$@<A\*]B4A/\H _2OM I2E I2E I2E I2E I2E
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M_E^->W0NAIFG[%=&;J['NT]\[&U/?RJ:;&&4JX'D ">'/-!8QK_9Y2EIBW6
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MPSNJ+&U=$6YRZ14S5KZM+17Q*_Z<\L_#G08#T[KOR7;_ *V/VJ>G==^2[?\
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M15$Z_JWWT,*?C)F.%;JPXX1'9VI.X9&/:. ,CGQQLRU:'MEOL<6R]9*D6B,
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ME.A:(YP0-N "< D J)QGA0:_TC+@1K9K"^OC%KL"5V2W-+X]6TR@!7#O4M9
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M2N';FBC*7DI)99]GOWK4I1\<_"MFM:3A,N7QV._+:DWEP+E/I6"O 3M"4Y!
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;"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4'__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
